PLoS ONE (Jan 2013)

Neuroprotective effect of a new synthetic aspirin-decursinol adduct in experimental animal models of ischemic stroke.

  • Bing Chun Yan,
  • Joon Ha Park,
  • Bich Na Shin,
  • Ji Hyeon Ahn,
  • In Hye Kim,
  • Jae-Chul Lee,
  • Ki-Yeon Yoo,
  • In Koo Hwang,
  • Jung Hoon Choi,
  • Jeong Ho Park,
  • Yun Lyul Lee,
  • Hong-Won Suh,
  • Jong-Gab Jun,
  • Young-Guen Kwon,
  • Young-Myeong Kim,
  • Seung-Hae Kwon,
  • Song Her,
  • Jin Su Kim,
  • Byung-Hwa Hyun,
  • Chul-Kyu Kim,
  • Jun Hwi Cho,
  • Choong Hyun Lee,
  • Moo-Ho Won

DOI
https://doi.org/10.1371/journal.pone.0074886
Journal volume & issue
Vol. 8, no. 9
p. e74886

Abstract

Read online

Stroke is the second leading cause of death. Experimental animal models of cerebral ischemia are widely used for researching mechanisms of ischemic damage and developing new drugs for the prevention and treatment of stroke. The present study aimed to comparatively investigate neuroprotective effects of aspirin (ASA), decursinol (DA) and new synthetic aspirin-decursinol adduct (ASA-DA) against transient focal and global cerebral ischemic damage. We found that treatment with 20 mg/kg, not 10 mg/kg, ASA-DA protected against ischemia-induced neuronal death after transient focal and global ischemic damage, and its neuroprotective effect was much better than that of ASA or DA alone. In addition, 20 mg/kg ASA-DA treatment reduced the ischemia-induced gliosis and maintained antioxidants levels in the corresponding injury regions. In brief, ASA-DA, a new synthetic drug, dramatically protected neurons from ischemic damage, and neuroprotective effects of ASA-DA may be closely related to the attenuation of ischemia-induced gliosis and maintenance of antioxidants.